Clinical trial
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of…
NCT02878330 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT02878330 |
|---|---|
| Title | A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. |
| Official title | A Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants |
| Acronym | MEDI8897 Ph2b |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Respiratory Syncytial Virus Infections |
| Intervention type | Drug |
| Interventions | MEDI8897, Placebo |
| Enrollment | 1,453 |
| Start date | Nov 3, 2016 |
| Primary completion | Jul 17, 2018 |
| Completion | Dec 6, 2018 |
| First posted | Aug 25, 2016 |
| Last update posted | Oct 14, 2019 |
| Countries | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, Estonia, Finland, France, Hungary and 11 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: